Superworth

Globus Medical EPS GMED

Diluted earnings per share by quarter and over the last twelve months, from 2011.

Last 12 months, to Jun 30, 2026
$3.91
Latest quarter, Q2 FY26
$1.10
−26% on a year earlier
Fiscal year 2025
$3.94
+425% on the year before

Globus Medical's earnings per share was $3.91 over the twelve months to Jun 30, 2026, up 50% on a year earlier.

In its latest quarter, Q2 FY26, it was $1.10, down 26% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 32% a year on average.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025$3.94+425%
FY2024$0.75−36%
FY2023$1.18−37%
FY2022$1.86+30%
FY2021$1.43+43%
FY2020$1.00−35%
FY2019$1.53−1%
FY2018$1.54+40%
FY2017$1.10+2%
FY2016$1.08−8%
FY2015$1.18+22%
FY2014$0.97+33%
FY2013$0.73−9%
FY2012$0.80−22%
FY2011$1.02n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$1.10−26%$3.91
Q1 FY26$0.90+67%$4.30
Q4 FY25$1.03+442%$3.94
Q3 FY25$0.88+132%$3.10
Q2 FY25$1.49+548%$2.60
Q1 FY25$0.54n/a$1.34
Q4 FY24$0.19+58%$0.75
Q3 FY24$0.38+3700%$0.68
Q2 FY24$0.23−60%$0.31
Q1 FY24−$0.05−110%$0.65
Q4 FY23$0.12−76%$1.18
Q3 FY23$0.01−98%$1.55

Against its peers

Companies in Medical - Instruments & Supplies nearest Globus Medical's size, closest first, today.

CompanyEPS, 12 monthsGrowth
GMEDGlobus Medical$3.91+50% a year
ALGNAlign Technology$5.75−3% a year
PODDInsulet$5.35+64% a year
COOCooper Companies$2.93+44% a year
PENPenumbra$4.07+8% a year
SOLVSolventum$8.18+277% a year
MSAMSA Safety$8.04+15% a year
MMSIMerit Medical Systems$2.42+23% a year
HAEHaemonetics$2.04−38% a year
VNTVontier$2.41−8% a year
BMIBadger Meter$4.28−8% a year
Peer median$4.17

Where Globus Medical ranks

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Globus Medical

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.